Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.45 |
| ▸ | MLNR | O43193 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160366 | 0.83 | EGLN1 (0.47) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| SCHEMBL6160758 | 0.81 | EGLN1 (0.51) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| SCHEMBL6158886 | 0.81 | EGLN1 (0.48) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| SCHEMBL6158883 | 0.81 | EGLN1 (0.48) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| SCHEMBL6161160 | 0.80 | EGLN1 (0.46) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| SCHEMBL6160335 | 0.80 | EGLN1 (0.48) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| SCHEMBL6162075 | 0.79 | EGLN1 (0.51) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| SCHEMBL6160356 | 0.79 | EGLN1 (0.46) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL6159472 | 0.79 | EGLN1 (0.50) | HTTEGLN1MLNRHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL6159638 | 0.79 | EGLN1 (0.50) | HTTEGLN1MLNRHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1500658-A1 | NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TST, QSOX1, MMP1 | HTT 581/4885EGLN1 841/4885MLNR 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.